Shares of Veru Inc. (NASDAQ:VERU) have earned an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $19.25.
Several brokerages have recently weighed in on VERU. Brookline Capital Management lifted their target price on shares of Veru from $13.00 to $17.00 in a report on Monday, December 14th. Zacks Investment Research upgraded shares of Veru from a “sell” rating to a “hold” rating in a research note on Thursday, February 18th. Cantor Fitzgerald raised their price objective on shares of Veru from $6.00 to $15.00 and gave the company an “overweight” rating in a research note on Monday, December 14th. Oppenheimer raised their price objective on shares of Veru from $19.00 to $24.00 in a research note on Thursday, February 11th. Finally, TheStreet cut shares of Veru from a “b-” rating to a “c” rating in a research note on Monday, March 29th.
In other Veru news, CEO Mitchell Shuster Steiner sold 20,000 shares of Veru stock in a transaction dated Friday, February 12th. The shares were sold at an average price of $20.88, for a total transaction of $417,600.00. Following the completion of the transaction, the chief executive officer now owns 7,184,767 shares in the company, valued at $150,017,934.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 26.10% of the company’s stock.
Shares of NASDAQ:VERU traded up $0.25 during midday trading on Friday, hitting $10.52. The stock had a trading volume of 30,519 shares, compared to its average volume of 4,057,851. The company has a market capitalization of $756.51 million, a PE ratio of -37.78 and a beta of 0.71. The stock has a 50 day moving average price of $13.65 and a two-hundred day moving average price of $8.06. Veru has a 1 year low of $2.30 and a 1 year high of $24.57.
Veru (NASDAQ:VERU) last issued its earnings results on Wednesday, February 10th. The company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.02. The business had revenue of $14.62 million for the quarter, compared to the consensus estimate of $10.63 million. Veru had a negative net margin of 44.55% and a negative return on equity of 23.72%. Equities analysts forecast that Veru will post -0.24 earnings per share for the current fiscal year.
Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.
Read More: How big is the FinTech market?
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.